RecallRadar

FDA Drug recall D-0844-2020

Memantine Hydrochloride Extended-release Capsules, 28mg, packaged in 100-count Unit Dose Cartons , Rx only, Manufactured for: Lupin Pharmac…

On 2020-02-26 the FDA classified a Class III recall of Memantine Hydrochloride Extended-release Capsules, 28mg, packaged in 100-count Unit Dose Cartons , Rx only, Manufactured for: Lupin Pharmac… by The Harvard Drug Group, citing failed Dissolution Specifications: High out of specification result observed at stability studies.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0844-2020
ClassificationClass III
Statusterminated
Initiated2019-12-13
Published2020-02-26
Last updated2026-09-13 11:52 UTC
CompanyThe Harvard Drug Group
DistributionUS

Product

Memantine Hydrochloride Extended-release Capsules, 28mg, packaged in 100-count Unit Dose Cartons , Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202 United States; Distributed by: Major Pharmaceuticals, 17177 N Laurel Park Dr., Suite 233, Livonia, MI 48152 USA, NDC 0904-6735-61

Reason

Failed Dissolution Specifications: High out of specification result observed at stability studies.

Identifiers

ndc0904-6734-61
ndc0904-6736-61
ndc0904-6737-61
ndc0904-6735-61
code_infoLot# M02465D

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0844-2020%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.